TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15743112

Group type: EXPERIMENTAL
Intervention: Thioctic acid at an oral dosage of 800 mg/day for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary supplementation with antioxidant micronutrients
Number of subjects: 0
Study: 11064772

Group type: EXPERIMENTAL
Intervention: Oral cefuroxime axetil for 10 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin (one dose)
Number of subjects: 86
Study: 9315571

Group type: EXPERIMENTAL
Intervention: Nonfatal unsatisfactory outcome end point (composite end point)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Nonfatal unsatisfactory outcome end point
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: New-onset severe congestive heart failure/shock
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <40%
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Recurrent myocardial infarction
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: TIMI flow grade <2 at 90 minutes
Number of subjects: 576
Study: 8364872

Group type: EXPERIMENTAL
Intervention: LC9018 combined with radiation therapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 228
Study: 3490334

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 47
Study: 31561326

Group type: EXPERIMENTAL
Intervention: HAL-SJ
Number of subjects: 22

Group type: COMPARATOR
Intervention: CPT
Number of subjects: 22
Study: 28541742

Group type: EXPERIMENTAL
Intervention: Warm communication style
Number of subjects: 89

Group type: COMPARATOR
Intervention: Neutral communication style
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Enhanced information about the placebo training program
Number of subjects: 89

Group type: COMPARATOR
Intervention: Basic information about the placebo training program
Number of subjects: 89
Study: 27090804

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LPS)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 662
Study: 25518099

Group type: EXPERIMENTAL
Intervention: Fitness programme offered by Fitness World
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Aerobics group sessions and gym sessions (for men)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Any activities (for women)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Time preference for fitness activities
Number of subjects: 58
Study: 22172305

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study: 20122682

Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF) transposition
Number of subjects: 145

Group type: COMPARATOR
Intervention: Karydakis flap reconstruction
Number of subjects: 145
Study: 18718738

Group type: COMPARATOR
Intervention: Endoscope
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Microscope
Number of subjects: 70
Study: 16205946

Group type: EXPERIMENTAL
Intervention: epirubicin (median cumulative dose: 450 mg/m2)
Number of subjects: 172

Group type: COMPARATOR
Intervention: doxorubicin (median cumulative dose: 240 mg/m2)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: epirubicin and doxorubicin
Number of subjects: 172
Study: 12838282

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cyclosporin A (CSA)
Number of subjects: 62
Study: 11339012

Group type: EXPERIMENTAL
Intervention: Magnesium levels in patients with MVPS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG) magnesium levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of magnesium levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Evaluation of magnesium deficiency
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Histograms of magnesium concentration values
Number of subjects: 50
Study: 8976466

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (PST)
Number of subjects: 0
Study: 1732343

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 14
Study: 6397332

Group type: EXPERIMENTAL
Intervention: Spiramycin 500 mg 3-times daily for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erythromycin 500 mg 3-times daily for 5 days
Number of subjects: 100
Study: 30089580

Group type: EXPERIMENTAL
Intervention: Gadolinium magnetic resonance imaging (Gd‐MRI)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Repeated 18 F‐fludeoxyglucose positron emission tomography (18F‐FDG‐PET) imaging
Number of subjects: 2
Study: 30721586

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg + Furosemide 20 mg (TH group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg + Furosemide 20 mg (TI group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Furosemide 40 mg + Spironolactone 50 mg (C group)
Number of subjects: 64
Study: 24709498

Group type: EXPERIMENTAL
Intervention: Crystalloid + albumin group (n=33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Crystalloid group (n=30)
Number of subjects: 63
Study: 23163605

Group type: EXPERIMENTAL
Intervention: Negative-restrictive slogans (e.g., 'Don't drink')
Number of subjects: 91
Study: 20230352

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18166312

Group type: EXPERIMENTAL
Intervention: Adequate prenatal care (Kotelchuck index)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Inadequate prenatal care (Kotelchuck index)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Unscheduled obstetric visits
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Multiple unscheduled visits
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Additional unscheduled encounters
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Predictors of unscheduled visits
Number of subjects: 420
Study: 15671112

Group type: EXPERIMENTAL
Intervention: hCG (10,000 IU, single IM injection on day 19)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg intravaginally, days 18-27)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (natural cycle)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 12
Study: 12025445

Group type: EXPERIMENTAL
Intervention: Iron therapy for children with IDA after a 3-month follow-up period.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (children without IDA).
Number of subjects: 35
Study: 10346547

Group type: EXPERIMENTAL
Intervention: Intervention practices (using patient self-assessment data)
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Usual care practices (control group)
Number of subjects: 1651
Study: 8600086

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sequential PCI
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Concurrent or sandwiched PCI
Number of subjects: 51

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 51
Study: 11188598

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: JRA patients
Number of subjects: 32
Study: 6179344

Group type: EXPERIMENTAL
Intervention: Oral retinoids in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no retinoids, only chemotherapy with bleomycin, cyclophosphamide, and prednisone)
Number of subjects: 10
Study: 31260437

Group type: EXPERIMENTAL
Intervention: Single-segment fixation (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Double-segment fixation (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple-segment fixation (Group C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Upper adjacent segments
Number of subjects: 18
Study: 28212652

Group type: EXPERIMENTAL
Intervention: In-person behavioural support
Number of subjects: 68

Group type: COMPARATOR
Intervention: Self-help booklet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 4-week reduction programme
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 16-week reduction programme
Number of subjects: 68
Study: 25639187

Group type: EXPERIMENTAL
Intervention: Early, ED-based referrals to palliative care
Number of subjects: 134

Group type: COMPARATOR
Intervention: Care as usual (physician-driven consultation)
Number of subjects: 134
Study: 24320695

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS) of 30 Hz applied for suprahyoid muscles for 10 min (total 1200 pulses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation applied for 10 min at the same site
Number of subjects: 20
Study: 23017355

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 81

Group type: COMPARATOR
Intervention: PI/r
Number of subjects: 81
Study: 19573999

Group type: EXPERIMENTAL
Intervention: Integrated group therapy (12 sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group drug counseling (control)
Number of subjects: 61
Study: 17371430

Group type: EXPERIMENTAL
Intervention: Patients with no experience of clinical trials
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients who had previously participated in an RCT
Number of subjects: 78

Group type: COMPARATOR
Intervention: Research nurses
Number of subjects: 78

Group type: COMPARATOR
Intervention: Comparison between patient groups
Number of subjects: 78
Study: 16734121

Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor (bFGF) in serum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soluble E-selectin (sE-sel) in serum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel in synovial fluid (SF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel correlation with functional class stages
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bFGF in SF and joint derangement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel correlation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel with clinical parameters
Number of subjects: 30
Study: 11705417

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 0
Study: 11059999

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (induced by a 100 g amino acid drink following an overnight fast)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control drink (placebo)
Number of subjects: 19
Study: 9103106

Group type: EXPERIMENTAL
Intervention: Critical time intervention plus usual services
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 96
Study: 9114915

Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered at mid-meal (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered 1 hour after mid-meal (group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered 2 hours after mid-meal (group C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (group D) administered 2 hours after mid-meal
Number of subjects: 24
Study: 3540876

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketorolac 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31594895

Group type: EXPERIMENTAL
Intervention: In-depth interviews with patients regarding their experiences accessing care for hypertension.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Public education on hypertension and better communication between healthcare professionals and patients.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reminders from family members for adherence to antihypertensive medications.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Training healthcare professionals for effective communication.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Awareness of the names or purpose of their medications.
Number of subjects: 20
Study: 29467829

Group type: EXPERIMENTAL
Intervention: Surgical offloading procedure (percutaneous flexor tenotomy, mini‐invasive floating metatarsal osteotomy or Keller arthroplasty)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Best available non-surgical treatment (offloading cast applied for up to 12 weeks)
Number of subjects: 100
Study: 27480291

Group type: EXPERIMENTAL
Intervention: Ligation of major branches during ITA anastomosis to the left anterior descending (LAD) coronary artery (Group I, 25 patients)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No ligation of major branches during ITA anastomosis (Group II, 28 patients)
Number of subjects: 53
Study: 24041199

Group type: EXPERIMENTAL
Intervention: Tailored Internet-based guided self-help treatment (8 weeks)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Standardized disorder-specific Internet-based treatment (8 weeks)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 132
Study: 22751757

Group type: EXPERIMENTAL
Intervention: Blended ALS training (1-day course supplemented with e-learning)
Number of subjects: 3732

Group type: COMPARATOR
Intervention: Conventional ALS training (2-day course)
Number of subjects: 3732
Study: 20362834

Group type: EXPERIMENTAL
Intervention: Group 1: Anterior capsular release including the anterior band of the IGHL
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group 2: Extended release inferiorly and posteriorly
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control: No additional release of the inferior glenohumeral ligament
Number of subjects: 74
Study: 18407004

Group type: EXPERIMENTAL
Intervention: Unconditional incentives
Number of subjects: 12289

Group type: EXPERIMENTAL
Intervention: $2 bill prepaid incentive and promise of $20 for retention
Number of subjects: 12289

Group type: EXPERIMENTAL
Intervention: Higher-value incentives
Number of subjects: 12289

Group type: EXPERIMENTAL
Intervention: Small prepaid monetary incentive ($2 or $5)
Number of subjects: 12289
Study: 15611004

Group type: COMPARATOR
Intervention: Standard tibial fixation with 7 x 25‐mm metal interference screw
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metal interference screw with supplementary staple fixation
Number of subjects: 56
Study: 12058094

Group type: EXPERIMENTAL
Intervention: Extended-release divalproex sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10474762

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 1070
Study: 8528115

Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) imaging during voluntary breathing maneuvers in humans and artificial ventilation in pigs.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EIT during artificial ventilation at different ventilation rates and during stepwise passive emptying and filling of lungs.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EIT functional imaging with 16 electrodes placed around the thorax.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EIT with additional evaluation procedure of functional imaging.
Number of subjects: 17
Study: 1961623

Group type: EXPERIMENTAL
Intervention: Pure oxygen (3 L/min) by a nasal probe
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no pure oxygen)
Number of subjects: 31
Study: 31471739

Group type: EXPERIMENTAL
Intervention: WLI-NBI cystoscopy
Number of subjects: 600

Group type: COMPARATOR
Intervention: WLI-WLI cystoscopy
Number of subjects: 600
Study: 30376108

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Valaciclovir and Placebo
Number of subjects: 198
Study: 28923375

Group type: EXPERIMENTAL
Intervention: Feldenkrais Method (FM) - Awareness Through Movement classes (30 classes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG) - no movement-based intervention
Number of subjects: 32
Study: 25516497

Group type: EXPERIMENTAL
Intervention: Prenatal Vitamin C and E supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no Vitamin C and E supplementation)
Number of subjects: 0
Study: 23802602

Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention, where key workers are trained to use DIALOG+ with each patient over a six-month period.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group where patients rate their satisfaction with life and treatment on a tablet.
Number of subjects: 180
Study: 21075600

Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: UCSD Performance-based Skills Assessment-Brief (UPSA-B)
Number of subjects: 323
Study: 19107321

Group type: EXPERIMENTAL
Intervention: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control foot (no treatment)
Number of subjects: 22
Study: 17531577

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 740

Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 740

Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 740
Study: 15356085

Group type: EXPERIMENTAL
Intervention: Flutamide (62.5 mg/d) plus metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month) without flutamide
Number of subjects: 40
Study: 11425999

Group type: EXPERIMENTAL
Intervention: Prone MR imaging in Group 1 (healthy volunteers and patients with herniated disk)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supine MR imaging in Group 3 (patients who previously had tethered cord surgery)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supine MR imaging in Group 2 (patients clinically suspected of having a tethered cord)
Number of subjects: 56
Study: 9722840

Group type: EXPERIMENTAL
Intervention: PTA with selective stent placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary stent placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 0
Study: 8162994

Group type: EXPERIMENTAL
Intervention: Averaging several forced expirations
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single curves selected in eight different ways
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prior inhalation of a bronchodilator aerosol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Truncation by volume at levels between 75‐99% of forced vital capacity (FVC)
Number of subjects: 46
Study: 2607590

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 6

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 6
Study: 824535

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 40 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 40 mg with ethanol (0-75 g/kg)
Number of subjects: 17
Study: 31218390

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 160

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 160
Study: 31889152

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (n=37)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard anticoagulation (enoxaparin and warfarin, n=35)
Number of subjects: 72
Study: 27938498

Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 108
Study: 25444990

Group type: EXPERIMENTAL
Intervention: Modified Z Trendelenburg position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trendelenburg position
Number of subjects: 50
Study: 23530484

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD) therapy alone
Number of subjects: 1781
Study: 21570509

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 15570

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 15570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15570
Study: 19571570

Group type: EXPERIMENTAL
Intervention: Food challenge test (double-blind, placebo-controlled)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Food challenge test (in patients with respiratory reactions)
Number of subjects: 40
Study: 16753049

Group type: EXPERIMENTAL
Intervention: Outpatient polypectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Daycase polypectomy
Number of subjects: 40
Study: 15630143

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.5 g x kg(−1) body mass in 1.5 litres of solution)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink (equal volume)
Number of subjects: 10
Study: 11049837

Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9274760

Group type: EXPERIMENTAL
Intervention: Binocular visual direction with adjacent binocular objects; specific intervention details such as dosage and duration are not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocular objects viewed in the presence of adjacent binocular objects; specific intervention details such as dosage and duration are not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonius lines as indicators of eye position; specific intervention details such as dosage and duration are not available.
Number of subjects: 0
Study: 8453969

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg bid for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3739581

Group type: EXPERIMENTAL
Intervention: Supplementary dose of 20 ml mepivacaine 1% with adrenaline
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no supplementary dose)
Number of subjects: 233